Clearside Biomedical (NASDAQ:CLSD) posted its quarterly earnings data on Thursday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.12), Fidelity Earnings reports.
NASDAQ:CLSD traded down $0.14 during trading hours on Friday, hitting $1.84. 707,532 shares of the stock traded hands, compared to its average volume of 703,408. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.94 and a quick ratio of 7.94. Clearside Biomedical has a 1 year low of $1.83 and a 1 year high of $15.33. The company has a market capitalization of $70.13 million, a P/E ratio of -0.79 and a beta of -3.98.
Large investors have recently modified their holdings of the business. Voya Investment Management LLC purchased a new position in Clearside Biomedical during the second quarter valued at approximately $123,000. Point72 Asset Management L.P. purchased a new position in Clearside Biomedical during the second quarter valued at approximately $2,138,000. BlackRock Inc. lifted its holdings in Clearside Biomedical by 53.1% during the second quarter. BlackRock Inc. now owns 1,859,948 shares of the company’s stock valued at $19,883,000 after purchasing an additional 645,292 shares in the last quarter. Alps Advisors Inc. purchased a new position in Clearside Biomedical during the second quarter valued at approximately $496,000. Finally, GSA Capital Partners LLP purchased a new position in Clearside Biomedical during the second quarter valued at approximately $534,000. 62.23% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Clearside Biomedical (CLSD) Posts Earnings Results, Misses Estimates By $0.12 EPS” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2018/11/10/clearside-biomedical-clsd-posts-earnings-results-misses-estimates-by-0-12-eps.html.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.
Recommended Story: Understanding Stock Ratings
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.